NYSE:COO

The Cooper Companies Competitors

$386.05
+5.03 (+1.32 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$380.11
Now: $386.05
$386.05
50-Day Range
$371.56
MA: $384.62
$392.57
52-Week Range
$268.92
Now: $386.05
$401.92
Volume277,338 shs
Average Volume286,438 shs
Market Capitalization$18.97 billion
P/E Ratio80.26
Dividend Yield0.02%
Beta0.82

Competitors

The Cooper Companies (NYSE:COO) Vs. ALGN, WST, XRAY, HAE, STAA, and QDEL

Should you be buying COO stock or one of its competitors? Companies in the sub-industry of "health care supplies" are considered alternatives and competitors to The Cooper Companies, including Align Technology (ALGN), West Pharmaceutical Services (WST), DENTSPLY SIRONA (XRAY), Haemonetics (HAE), STAAR Surgical (STAA), and Quidel (QDEL).

The Cooper Companies (NYSE:COO) and Align Technology (NASDAQ:ALGN) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership and valuation.

Profitability

This table compares The Cooper Companies and Align Technology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
The Cooper Companies9.81%12.79%7.20%
Align Technology76.00%68.99%46.64%

Analyst Ratings

This is a summary of recent recommendations for The Cooper Companies and Align Technology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
The Cooper Companies04602.60
Align Technology13902.62

The Cooper Companies currently has a consensus target price of $384.25, indicating a potential downside of 0.47%. Align Technology has a consensus target price of $501.3333, indicating a potential downside of 15.40%. Given The Cooper Companies' higher possible upside, equities research analysts clearly believe The Cooper Companies is more favorable than Align Technology.

Insider & Institutional Ownership

95.8% of The Cooper Companies shares are held by institutional investors. Comparatively, 85.8% of Align Technology shares are held by institutional investors. 1.4% of The Cooper Companies shares are held by company insiders. Comparatively, 1.2% of Align Technology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares The Cooper Companies and Align Technology's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Cooper Companies$2.43 billion7.81$238.40 million$9.6440.05
Align Technology$2.41 billion19.48$442.78 million$4.96119.47

Align Technology has lower revenue, but higher earnings than The Cooper Companies. The Cooper Companies is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

The Cooper Companies has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, Align Technology has a beta of 1.68, indicating that its stock price is 68% more volatile than the S&P 500.

Summary

Align Technology beats The Cooper Companies on 8 of the 14 factors compared between the two stocks.

West Pharmaceutical Services (NYSE:WST) and The Cooper Companies (NYSE:COO) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.

Profitability

This table compares West Pharmaceutical Services and The Cooper Companies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
West Pharmaceutical Services14.69%19.01%12.78%
The Cooper Companies9.81%12.79%7.20%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for West Pharmaceutical Services and The Cooper Companies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
West Pharmaceutical Services01202.67
The Cooper Companies04602.60

West Pharmaceutical Services currently has a consensus price target of $310.00, indicating a potential upside of 4.55%. The Cooper Companies has a consensus price target of $384.25, indicating a potential downside of 0.47%. Given West Pharmaceutical Services' stronger consensus rating and higher probable upside, analysts plainly believe West Pharmaceutical Services is more favorable than The Cooper Companies.

Volatility and Risk

West Pharmaceutical Services has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, The Cooper Companies has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500.

Dividends

West Pharmaceutical Services pays an annual dividend of $0.68 per share and has a dividend yield of 0.2%. The Cooper Companies pays an annual dividend of $0.06 per share and has a dividend yield of 0.0%. West Pharmaceutical Services pays out 21.0% of its earnings in the form of a dividend. The Cooper Companies pays out 0.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. West Pharmaceutical Services has increased its dividend for 25 consecutive years and The Cooper Companies has increased its dividend for 1 consecutive years. West Pharmaceutical Services is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Insider and Institutional Ownership

92.6% of West Pharmaceutical Services shares are held by institutional investors. Comparatively, 95.8% of The Cooper Companies shares are held by institutional investors. 1.6% of West Pharmaceutical Services shares are held by insiders. Comparatively, 1.4% of The Cooper Companies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares West Pharmaceutical Services and The Cooper Companies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
West Pharmaceutical Services$1.84 billion11.90$241.70 million$3.2491.52
The Cooper Companies$2.43 billion7.81$238.40 million$9.6440.05

West Pharmaceutical Services has higher earnings, but lower revenue than The Cooper Companies. The Cooper Companies is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Summary

West Pharmaceutical Services beats The Cooper Companies on 11 of the 17 factors compared between the two stocks.

DENTSPLY SIRONA (NASDAQ:XRAY) and The Cooper Companies (NYSE:COO) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings and institutional ownership.

Earnings & Valuation

This table compares DENTSPLY SIRONA and The Cooper Companies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DENTSPLY SIRONA$4.03 billion3.49$262.90 million$2.4526.20
The Cooper Companies$2.43 billion7.81$238.40 million$9.6440.05

DENTSPLY SIRONA has higher revenue and earnings than The Cooper Companies. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than The Cooper Companies, indicating that it is currently the more affordable of the two stocks.

Dividends

DENTSPLY SIRONA pays an annual dividend of $0.40 per share and has a dividend yield of 0.6%. The Cooper Companies pays an annual dividend of $0.06 per share and has a dividend yield of 0.0%. DENTSPLY SIRONA pays out 16.3% of its earnings in the form of a dividend. The Cooper Companies pays out 0.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. DENTSPLY SIRONA has increased its dividend for 1 consecutive years and The Cooper Companies has increased its dividend for 1 consecutive years.

Profitability

This table compares DENTSPLY SIRONA and The Cooper Companies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DENTSPLY SIRONA-1.40%7.13%4.13%
The Cooper Companies9.81%12.79%7.20%

Volatility and Risk

DENTSPLY SIRONA has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Comparatively, The Cooper Companies has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for DENTSPLY SIRONA and The Cooper Companies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DENTSPLY SIRONA15702.46
The Cooper Companies04602.60

DENTSPLY SIRONA presently has a consensus price target of $55.3333, indicating a potential downside of 13.81%. The Cooper Companies has a consensus price target of $384.25, indicating a potential downside of 0.47%. Given The Cooper Companies' stronger consensus rating and higher possible upside, analysts plainly believe The Cooper Companies is more favorable than DENTSPLY SIRONA.

Insider and Institutional Ownership

96.0% of DENTSPLY SIRONA shares are owned by institutional investors. Comparatively, 95.8% of The Cooper Companies shares are owned by institutional investors. 0.5% of DENTSPLY SIRONA shares are owned by company insiders. Comparatively, 1.4% of The Cooper Companies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

The Cooper Companies beats DENTSPLY SIRONA on 10 of the 16 factors compared between the two stocks.

Haemonetics (NYSE:HAE) and The Cooper Companies (NYSE:COO) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation and Earnings

This table compares Haemonetics and The Cooper Companies' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Haemonetics$988.48 million6.02$76.53 million$3.3135.37
The Cooper Companies$2.43 billion7.81$238.40 million$9.6440.05

The Cooper Companies has higher revenue and earnings than Haemonetics. Haemonetics is trading at a lower price-to-earnings ratio than The Cooper Companies, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

96.2% of Haemonetics shares are held by institutional investors. Comparatively, 95.8% of The Cooper Companies shares are held by institutional investors. 1.6% of Haemonetics shares are held by company insiders. Comparatively, 1.4% of The Cooper Companies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Haemonetics and The Cooper Companies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Haemonetics11.76%22.85%10.40%
The Cooper Companies9.81%12.79%7.20%

Analyst Ratings

This is a summary of recent recommendations and price targets for Haemonetics and The Cooper Companies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Haemonetics00403.00
The Cooper Companies04602.60

Haemonetics presently has a consensus price target of $144.80, indicating a potential upside of 23.70%. The Cooper Companies has a consensus price target of $384.25, indicating a potential downside of 0.47%. Given Haemonetics' stronger consensus rating and higher possible upside, equities analysts clearly believe Haemonetics is more favorable than The Cooper Companies.

Risk and Volatility

Haemonetics has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, The Cooper Companies has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500.

STAAR Surgical (NASDAQ:STAA) and The Cooper Companies (NYSE:COO) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Risk and Volatility

STAAR Surgical has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, The Cooper Companies has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500.

Profitability

This table compares STAAR Surgical and The Cooper Companies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
STAAR Surgical5.73%8.99%7.12%
The Cooper Companies9.81%12.79%7.20%

Earnings & Valuation

This table compares STAAR Surgical and The Cooper Companies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
STAAR Surgical$150.18 million35.95$14.05 million$0.46252.07
The Cooper Companies$2.43 billion7.81$238.40 million$9.6440.05

The Cooper Companies has higher revenue and earnings than STAAR Surgical. The Cooper Companies is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

85.4% of STAAR Surgical shares are held by institutional investors. Comparatively, 95.8% of The Cooper Companies shares are held by institutional investors. 3.9% of STAAR Surgical shares are held by insiders. Comparatively, 1.4% of The Cooper Companies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for STAAR Surgical and The Cooper Companies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
STAAR Surgical03302.50
The Cooper Companies04602.60

STAAR Surgical presently has a consensus target price of $68.50, indicating a potential downside of 40.92%. The Cooper Companies has a consensus target price of $384.25, indicating a potential downside of 0.47%. Given The Cooper Companies' stronger consensus rating and higher probable upside, analysts clearly believe The Cooper Companies is more favorable than STAAR Surgical.

Summary

The Cooper Companies beats STAAR Surgical on 10 of the 14 factors compared between the two stocks.

The Cooper Companies (NYSE:COO) and Quidel (NASDAQ:QDEL) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.

Valuation and Earnings

This table compares The Cooper Companies and Quidel's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Cooper Companies$2.43 billion7.81$238.40 million$9.6440.05
Quidel$534.89 million9.75$72.92 million$2.7345.13

The Cooper Companies has higher revenue and earnings than Quidel. The Cooper Companies is trading at a lower price-to-earnings ratio than Quidel, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

95.8% of The Cooper Companies shares are owned by institutional investors. Comparatively, 84.0% of Quidel shares are owned by institutional investors. 1.4% of The Cooper Companies shares are owned by insiders. Comparatively, 14.1% of Quidel shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares The Cooper Companies and Quidel's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
The Cooper Companies9.81%12.79%7.20%
Quidel36.91%63.31%40.55%

Risk and Volatility

The Cooper Companies has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Quidel has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for The Cooper Companies and Quidel, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
The Cooper Companies04602.60
Quidel10302.50

The Cooper Companies currently has a consensus target price of $384.25, suggesting a potential downside of 0.47%. Quidel has a consensus target price of $262.75, suggesting a potential upside of 113.27%. Given Quidel's higher possible upside, analysts plainly believe Quidel is more favorable than The Cooper Companies.

Summary

The Cooper Companies beats Quidel on 8 of the 14 factors compared between the two stocks.


The Cooper Companies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Align Technology logo
ALGN
Align Technology
1.9$592.56+2.8%$46.89 billion$2.41 billion26.96Analyst Downgrade
Gap Up
West Pharmaceutical Services logo
WST
West Pharmaceutical Services
1.9$296.52+1.6%$21.90 billion$1.84 billion78.24
DENTSPLY SIRONA logo
XRAY
DENTSPLY SIRONA
2.0$64.20+0.1%$14.06 billion$4.03 billion-279.13
Haemonetics logo
HAE
Haemonetics
1.6$117.06+2.8%$5.95 billion$988.48 million56.55Gap Up
STAAR Surgical logo
STAA
STAAR Surgical
1.4$115.95+0.8%$5.40 billion$150.18 million610.30
Quidel logo
QDEL
Quidel
2.4$123.20+4.2%$5.21 billion$534.89 million14.46Gap Down
Neogen logo
NEOG
Neogen
1.2$92.55+2.0%$4.95 billion$418.17 million81.18
ICU Medical logo
ICUI
ICU Medical
1.5$204.19+0.1%$4.33 billion$1.27 billion54.02
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.5$61.50+1.5%$3.42 billion$994.85 million-116.04News Coverage
Atrion logo
ATRI
Atrion
1.1$644.00+0.3%$1.18 billion$155.07 million36.28
Meridian Bioscience logo
VIVO
Meridian Bioscience
1.7$25.04+2.8%$1.08 billion$253.67 million23.19Analyst Downgrade
Gap Down
Cerus logo
CERS
Cerus
1.7$6.13+1.0%$1.03 billion$74.65 million-15.72Analyst Upgrade
Analyst Revision
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.42+0.3%$749.68 million$154.60 million-45.30
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.10+0.5%$689.46 million$123.86 million68.34Analyst Upgrade
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$39.80+1.7%$570.33 million$114.51 million-84.68News Coverage
Utah Medical Products logo
UTMD
Utah Medical Products
0.9$87.54+1.0%$319.17 million$46.90 million27.62News Coverage
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.